Clinical effects of proton pump inhibitors: Focus on pharmacogenetics, kinetics and dynamics
(Klinische effecten van proton pomp remmers: Focus op farmacogenetica, kinetiek en dynamiek)
2010-09-24
Doctoral Thesis
| Related Files |
|---|
View PDF Version
(100924_Hunfeld, Nicole Geertruida Maria.pdf, 4.3MB) |
|
View PDF Version
(stellingen N Hunfeld.pdf, 0.2MB) |
This thesis describes the clinical effects of proton pump inhibitors, with focus on pharmacogenetics, kinetics and dynamics. The aims were to investigate the occurence of Rebound Acid Hypersecretion and to investigate the speed of onset, the duration of effect and the difference in acid-inhibition between esomeprazole, rabeprazole and pantoprazole. Furthermore the prevalence of CYP2C19 polymorphism was studied in a Caucasian population. The influence of CYP2C19 polymorphism on acid-inhibition and pharmacokinetics of proton pump inhibitors in Caucasians was also studied.
Apotheek Haagse Ziekenhuizen,
AstraZeneca B.V.,
Bayer Schering Pharma,
Fresenius-Kabi B.V.,
HagaZiekenhuis,
Inge Voesten-Appel stichting,
Nederlandse Vereniging voor Gastroenterologie
- pharmacodynamics
- pharmacogenetics
- pharmacokinetics
- CYP2C19
- esomeprazole
- PPIs
- intragastric pH
- lansoprazole
- omeprazole
- pantoprazole
- proton pump inhibitors
- rabeprazol
- rebound acid hypersecretion
- study
- subject
- rabeprazole
- effect
- esomeprazole
- genotype
- intragastric ph
- cyp 2c
- intragastric
- pantoprazole
- omeprazole
- cyp 2c polymorphism
- esomeprazole 40 mg
- pharmacol
- aliment pharmacol
- acidinhibitory effects
- treatment
- caucasian
- administration
- pantoprazole 40 mg
